Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Immunol ; 196(4): 1579-90, 2016 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-26783340

RESUMEN

Plasmacytoid dendritic cells (pDCs) produce large amounts of type I IFN in response to TLR7/9 ligands. This conveys antiviral effects, activates other immune cells (NK cells, conventional DCs, B, and T cells), and causes the induction and expansion of a strong inflammatory response. pDCs are key players in various type I IFN-driven autoimmune diseases such as systemic lupus erythematosus or psoriasis, but pDCs are also involved in (anti-)tumor immunity. The sphingolipid sphingosine-1-phosphate (S1P) signals through five G-protein-coupled receptors (S1PR1-5) to regulate, among other activities, immune cell migration and activation. The present study shows that S1P stimulation of human, primary pDCs substantially decreases IFN-α production after TLR7/9 activation with different types of CpG oligodeoxynucleotides or tick-borne encephalitis vaccine, which occurred in an S1PR4-dependent manner. Mechanistically, S1PR4 activation preserves the surface expression of the human pDC-specific inhibitory receptor Ig-like transcript 7. We provide novel information that Ig-like transcript 7 is rapidly internalized upon receptor-mediated endocytosis of TLR7/9 ligands to allow high IFN-α production. This is antagonized by S1PR4 signaling, thus decreasing TLR-induced IFN-α secretion. At a functional level, attenuated IFN-α production failed to alter Ag-driven T cell proliferation in pDC-dependent T cell activation assays, but shifted cytokine production of T cells from a Th1 (IFN-γ) to a regulatory (IL-10) profile. In conclusion, S1PR4 agonists block human pDC activation and may therefore be a promising tool to restrict pathogenic IFN-α production.


Asunto(s)
Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Interferón-alfa/biosíntesis , Receptores Inmunológicos/fisiología , Receptores de Lisoesfingolípidos/metabolismo , Transducción de Señal , Diferenciación Celular , Movimiento Celular , Células Cultivadas , Citocinas/biosíntesis , Células Dendríticas/efectos de los fármacos , Humanos , Interferón-alfa/inmunología , Interleucina-10/biosíntesis , Activación de Linfocitos , Lisofosfolípidos/inmunología , Lisofosfolípidos/farmacología , Oligodesoxirribonucleótidos/farmacología , Receptores Inmunológicos/inmunología , Esfingosina/análogos & derivados , Esfingosina/inmunología , Esfingosina/farmacología , Receptor Toll-Like 7/inmunología , Receptor Toll-Like 9/inmunología
2.
Acta Derm Venereol ; 98(6): 576-584, 2018 Jun 08.
Artículo en Inglés | MEDLINE | ID: mdl-29582898

RESUMEN

The effects of 8-Methoxypsoralen plus ultraviolet A (PUVA) or ultraviolet B (UVB) alone on imiquimod-induced psoriasis were examined in a mouse model. Mouse skin was treated with repetitive sub-phototoxic doses of PUVA or UVB before or during the induction of toll-like receptor 7/8 activation and psoriasis through the application of imiquimod. PUVA, to a greater degree than UVB, suppressed the established imiquimod-induced psoriatic phenotype, but pretreatment with PUVA prior to administration of imiquimod also reduced the susceptibility of murine skin to respond to imiquimod to a greater degree than did pretreatment with UVB. PUVA downregulated baseline levels of miRNA27a and 29a, as well as interferon-γ, interleukin-17 and -9, cytokines, which drive psoriatic inflammation. Microarray analysis showed enrichment of senescence pathway genes linked to upregulation of p16/p21 proteins after PUVA pretreatment. However, the anti-psoriatic effect of PUVA was lost when there was an interval of 7 days between final exposure to PUVA and the start of administration of imiquimod. This indicated that (UVB and) PUVA diminished imiquimod-induced established psoriatic inflammation, but also primed the skin in favour of a reduced responsiveness to toll-like receptor activation.


Asunto(s)
Aminoquinolinas , Metoxaleno/farmacología , Terapia PUVA , Fármacos Fotosensibilizantes/farmacología , Psoriasis/prevención & control , Piel/efectos de los fármacos , Animales , Citocinas/genética , Citocinas/metabolismo , Modelos Animales de Enfermedad , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Imiquimod , Ratones Endogámicos BALB C , Psoriasis/inducido químicamente , Psoriasis/genética , Psoriasis/metabolismo , Transducción de Señal/efectos de los fármacos , Piel/metabolismo , Piel/patología , Factores de Tiempo
3.
Acta Derm Venereol ; 97(9): 1087-1094, 2017 Oct 02.
Artículo en Inglés | MEDLINE | ID: mdl-28597024

RESUMEN

The mTOR (mechanistic target of rapamycin) inhibitor rapamycin has long been known for its immune suppressive properties, but it has shown limited therapeutic success when given systemically to patients with psoriasis. Recent data have shown that the mTOR pathway is hyperactivated in lesional psoriatic skin, which probably contributes to the disease by interfering with maturation of keratinocytes. This study investigated the effect of topical rapamycin treatment in an imiquimod-induced psoriatic mouse model. The disease was less severe if the mice had received rapamycin treatment. Immunohistological analysis revealed that rapamycin not only prevented the activation of mTOR signalling (P-mTOR and P-S6 levels), but almost normalized the expression of epidermal differentiation markers. In addition, the influx of innate immune cells into the draining lymph nodes was partially reduced by rapamycin treatment. These data emphasize the role of mTOR signalling in the pathogenesis of psoriasis, and support the investigation of topical mTOR inhibition as a novel anti-psoriatic strategy.


Asunto(s)
Inmunosupresores/farmacología , Psoriasis/tratamiento farmacológico , Sirolimus/farmacología , Serina-Treonina Quinasas TOR/antagonistas & inhibidores , Administración Tópica , Aminoquinolinas/efectos adversos , Animales , Caspasa 14/metabolismo , Células Dendríticas/metabolismo , Modelos Animales de Enfermedad , Imiquimod , Queratina-10/metabolismo , Queratina-14/metabolismo , Antígeno Ki-67/metabolismo , Células de Langerhans/metabolismo , Ganglios Linfáticos/metabolismo , Macrófagos/metabolismo , Proteínas de la Membrana/metabolismo , Ratones Endogámicos BALB C , Neovascularización Fisiológica/efectos de los fármacos , Precursores de Proteínas/metabolismo , Psoriasis/inducido químicamente , Piel/metabolismo
4.
Mediators Inflamm ; 2017: 6059203, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28848247

RESUMEN

The sphingolipid sphingosine-1-phosphate (S1P) emerges as an important regulator of immunity, mainly by signaling through a family of five specific G protein-coupled receptors (S1PR1-5). While S1P signaling generally has the potential to affect not only trafficking but also differentiation, activation, and survival of a diverse range of immune cells, the specific outcome depends on the S1P receptor repertoire expressed on a given cell. Among the S1PRs, S1PR4 is specifically abundant in immune cells, suggesting a major role of the S1P/S1PR4 axis in immunity. Recent studies indeed highlight its role in activation of immune cells, differentiation, and, potentially, trafficking. In this review, we summarize the emerging data that support a major role of S1PR4 in modulating immunity in humans and mice and discuss therapeutic implications.


Asunto(s)
Movimiento Celular/fisiología , Lisofosfolípidos/metabolismo , Esfingosina/análogos & derivados , Animales , Diferenciación Celular/fisiología , Movimiento Celular/genética , Humanos , Transducción de Señal/fisiología , Esfingosina/metabolismo
5.
Redox Biol ; 15: 12-21, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29195137

RESUMEN

AIM: NADPH oxidases are important sources of reactive oxygen species (ROS). Several Nox homologues are present together in the vascular system but whether they exhibit crosstalk at the activity level is unknown. To address this, vessel function of knockout mice for the cytosolic Nox organizer proteins p47phox, NoxO1 and a p47phox-NoxO1-double knockout were studied under normal condition and during streptozotocin-induced diabetes. RESULTS: In the mouse aorta, mRNA expression for NoxO1 was predominant in smooth muscle and endothelial cells, whereas p47phox was markedly expressed in adventitial cells comprising leukocytes and tissue resident macrophages. Knockout of either NoxO1 or p47phox resulted in lower basal blood pressure. Deletion of any of the two subunits also prevented diabetes-induced vascular dysfunction. mRNA expression analysis by MACE (Massive Analysis of cDNA ends) identified substantial gene expression differences between the mouse lines and in response to diabetes. Deletion of p47phox induced inflammatory activation with increased markers of myeloid cells and cytokine and chemokine induction. In contrast, deletion of NoxO1 resulted in an attenuated interferon gamma signature and reduced expression of genes related to antigen presentation. This aspect was also reflected by a reduced number of circulating lymphocytes in NoxO1-/- mice. INNOVATION AND CONCLUSION: ROS production stimulated by NoxO1 and p47phox limit endothelium-dependent relaxation and maintain blood pressure in mice. However, NoxO1 and p47phox cannot substitute each other despite their similar effect on vascular function. Deletion of NoxO1 induced an anti-inflammatory phenotype, whereas p47phox deletion rather elicited a hyper-inflammatory response.


Asunto(s)
Diabetes Mellitus Experimental/genética , NADPH Oxidasas/genética , Proteínas/genética , Proteínas Adaptadoras Transductoras de Señales , Animales , Aorta/metabolismo , Aorta/patología , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patología , Células Endoteliales/metabolismo , Expresión Génica , Humanos , Linfocitos/metabolismo , Linfocitos/patología , Ratones , Ratones Noqueados , NADP/metabolismo , NADPH Oxidasas/metabolismo , Unión Proteica , Especies Reactivas de Oxígeno/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA